Here’s what you should know:
1. Exact Sciences increased sales 158 percent, year-over-year.
2. Exact Sciences completed 161,000 Cologuard tests in the third quarter. Test volume grew 136 percent, year-over-year.
3. Cologuard earned approximately $451 per test.
4. Exact Sciences CEO Kevin Conroy said in a release, “A growing number of patients and physicians are demanding Cologuard. Through our direct-to-consumer television and marketing campaign and our national sales force, we are reaching a larger percentage of the 80 million people eligible to be screened with Cologuard.”
5. Concerning rest-of-year outlooks, Exact Sciences expects revenues between $254 million and $257 million for 2017. Exact Sciences estimates up to 177,000 more tests will be completed in the fourth quarter of 2017.
More articles on gastroenterology:
GI leader to know: Dr. Ravi Mallavarapu of Cedar Valley Gastroenterology
The VA has a high HCV treatment rate — 7 insights into why they’re so successful
5 latest findings on gut microbiome & human development
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
